Navigation Links
Advancing Research to Therapies for Brain Tumors Conference Connects Academic Scientists to Industry Investors

BOSTON, MA (PRWEB) July 23, 2013

National Brain Tumor Society, the largest nonprofit in the United States dedicated to the brain tumor community, recently hosted the inaugural Advancing Research to Therapies (ART) for Brain Tumors Conference in Washington, D.C. The ART Conference brought together more than 100 leading experts from academic research labs, government agencies, biotech and pharmaceutical companies, and venture capital firms to increase communication and collaboration, as well as discuss licensing and investment criteria for new drug candidates to speed the discovery of new treatments for brain tumor patients.

“With very few exceptions, the different stakeholders involved in brain tumor drug development don’t discuss the barriers they face, their particular needs and wants, and thus what needs to, and can, happen to get new and better therapies to patients,” said N. Paul TonThat, Executive Director, National Brain Tumor Society. “This was an unique opportunity to get everyone in a room, get all the issues on the table, and plot a course forward.”

Sponsored by Morgan, Lewis & Bockius LLP and BioHealth Innovation, the Conference engaged attendees, as well as participants, in a discussion surrounding the issues and criteria for advancing discoveries from academic labs, through the commercialization process, and into the hands of clinicians and patients. Specifically, audience and panelists sought to better understand why more treatments for brain tumors aren’t available despite recent gains in research.

To address the issues effecting brain tumor therapeutic development, three panels of experts shared their distinct perspectives on the R&D process:

  • VC Panel: Venture capitalists shared their conditions for determining whether to invest in a company, academic asset, or drug candidate
  • BioPharma Panel: Biotech and pharmaceutical company executives shared their criteria for determining whether to license and develop an academic asset or drug candidate
  • Federal Government Resources Panel: Employees from the National Institutes of Health/National Institute for Neurological Disease and Stroke outlined resources available for brain tumor researchers, in terms of both funding and advice, to translate discoveries into therapies

The panels discussed issues ranging from creating data packages big enough to show translatability and reproducibility (close to 70% of research fails to reproduce outside the original academic lab), to de-risking and simplifying the market for brain tumor drug development. Panelists also offered candid advice for researchers.

"If you're an academic looking to potentially take a program or an asset from your lab and trying to spin it out into a company, it's important as you begin to look at possible investors that you understand what their investment strategy is," said Michael Gutch, PhD, MD, and Managing Director of MedImmune Ventures.

"We invest in people we like to invest with,” added Neil Exter, Partner, Third Rock Ventures. “It's good to develop relationships with your friendly VCs in the nearer term, or over time."

Following the advice and subsequent discussions from Industry and government’s perspective, National Brain Tumor Society-funded academic researchers showcased their latest drug candidates in hopes of obtaining funding to move their asset toward clinical trials. Out of the four drug candidates presented, two of the corresponding researchers have already been in deeper discussions with Industry representatives that were on hand to seek licensing and development partnerships.

Nearly 700,000 people in the U.S. are living with a brain tumor, and close to 14,000 people will die because of the disease this year alone. Only one out of three adults diagnosed with a malignant brain tumor today will be alive in five years. More so than any other cancer, a brain tumor can have life-altering psychological, cognitive, behavioral, and physical effects. Yet, there are only four FDA approved drugs to treat brain tumors; only one is used in standard of care.

Panelists at the event included executives from SR One, Third Rock Ventures, MedImmune Ventures, Genentech/Roche, Pfizer, and Health Advances.

Medical academics presenting drug candidates included researchers from MD Anderson Cancer Center, Duke University, and University of Alabama Birmingham.

To learn more about the event and view/download presentations, please visit:

About National Brain Tumor Society
National Brain Tumor Society is the largest nonprofit organization dedicated to the brain tumor community in the United States. We are fiercely committed to finding better treatments, and ultimately a cure, for people living with a brain tumor today and those who will be diagnosed tomorrow. This means aggressively driving strategic research and advocating for public policies, which meet the critical needs of this community. To learn more visit

Read the full story at

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Novartis highlights new findings in advancing care for patients with 170 abstracts in breast, lung and blood cancers at ASCO and EHA
2. Advancing Preclinical Predictions, Making Faster Clinical Decisions with Cancer Models and Preclinical Imaging - World Pharma Congress this June in Philadelphia
3. 4th Annual Advancing Global Clinical Trials Conference is Announced
4. Astute Medical, Inc. Advancing Next Generation Acute Kidney Injury Biomarkers
5. CureLauncher is Described on LIVESTRONG Blog as Modern Platform That Gets People Involved in Advancing New Cancer Treatments
6. GenoSpace Announces the Launch of a Cloud-Based "Information Ecosystem" for Advancing 21st-Century Personalized Medicine
7. QIAGEN Partners with Exosome Diagnostics to Create High-Performance Biofluid Sample Preparation Kits for Personalized Healthcare Research
8. Medical Device and Drug Research, New Life Science Webinar Hosted by Xtalks
9. Global Activated Carbon Market 2012-2016: Latest Market Share, Growth, Analysis, Size, Trends & Forecast Research Report 2012-2016 Available at
10. Elliott Broidy Expands Role in Los Angeles Civics with Support of Stem Cell Research Program
11. New Research on Rapid Identification and Strain Typing of Salmonella in Food to Be Presented at IAFP
Post Your Comments:
(Date:10/13/2015)... SPRINGS, Florida , October 13, 2015 ... AVXLD), Juno Therapeutics, Inc. (NASDAQ: JUNO ), and ... ARRY ), Avanex Life Sciences Corp. (OTCQX: AVXLD), ... Pharmaceuticals, Inc. (NASDAQ: PGNX ) --> ... and the biotech industry can potentially lead to advancements ...
(Date:10/13/2015)... -- TapImmune, Inc. (TPIV), a clinical-stage ... and gene-based immunotherapeutics and vaccines for the treatment of ... company at the Dawson James Small Cap Growth ... Jupiter, Florida on October 15, 2015. ... immunotherapy company specializing in the development of innovative peptide ...
(Date:10/13/2015)... ... October 13, 2015 , ... Clinovo recently appointed Jeff Parr and ... fast growing clinical data solutions business. , Jeff Parr has spent the past decade ... including Avery Dennison, Thermo Fisher, and Ab Sciex to name a few. He ...
(Date:10/13/2015)... 13, 2015 the United States ... .  PRCC represents about 14% of all new cases of kidney ... Canada and Europe . ...   --> Hutchison China MediTech Limited ("Chi-Med") (AIM: HCM) ... and AstraZeneca AB (publ) ("AstraZeneca") have completed enrolment in a global ...
Breaking Biology Technology:
(Date:10/12/2015)... Research and Markets ( ) has announced the ... Market Shares, Strategies, and Forecasts, Worldwide, 2015-2021" to ... --> The study is designed to give a ... a selection from the mountains of data available of ... made by the most senior analysts. Commentary on every ...
(Date:10/12/2015)... , October 12, 2015 NXTD ) ... the growing mobile commerce market, reports on the recent SNS ... . --> NXTD ) ("NXT-ID" or the ... commerce market, reports on the recent SNS Future in Review ... --> NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or ...
(Date:10/9/2015)... 2015 ... "Samsung Galaxy S6 Fingerprint Sensor - ... offering. --> ) has ... Galaxy S6 Fingerprint Sensor - Reverse Costing ... --> Research and Markets ( ...
Breaking Biology News(10 mins):